The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Draft Guidelines & Recommendations for Juvenile Idiopathic Arthritis

Draft Guidelines & Recommendations for Juvenile Idiopathic Arthritis

March 19, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
 iLoveCoffeeDesign / shutterstock.com

iLoveCoffeeDesign / shutterstock.com

CHICAGO—The treatment of patients with juvenile idiopathic arthritis (JIA) is historically directed by clinical subtype. During a session at the 2018 ACR/ARHP Annual Meeting, speakers addressed the biological classification and treatment of JIA, discussing draft guidelines and recommendations, the impact of computer modeling on identifying JIA subtypes and subgroups of chronic arthritis.

You Might Also Like
  • New Genetic Loci Identified, Epigenome Explored in Juvenile Idiopathic Arthritis
  • Juvenile Idiopathic Arthritis
  • Patient Fact Sheet: Juvenile Idiopathic Arthritis
Explore This Issue
March 2019
Also By This Author
  • Patients with RA Who Respond to Treatment Experience Increased Cholesterol

Guidelines & Recommendations

Timothy Beukelman, MD, MSCE, associate professor of Pediatrics at the University of Alabama, Birmingham, opened the session by presenting the draft ACR and Arthritis Foundation guideline for the treatment of JIA. Although currently in draft form, significant changes to the recommendations are not anticipated during the approval process, Dr. Beukelman explained. The guideline reflects new developments in polyarthritis, including newly approved treatments and studies examining the effects of initial treatment choices. It also has an increased emphasis on sacroiliitis and addresses enthesitis for the first time.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The guideline includes 39 recommendations, and Dr. Beukelman highlighted select recommendations during the session. All recommendations required a 70% consensus, and each has a quality of evidence level and a strength of recommendation. Strong recommendations were issued when the panel was confident the desirable effects of the intervention outweighed the undesirable effects, as well as when the recommendation apply to almost all patients. Dr. Beukelman explained 80% of the recommendations were conditional rather than strong. Conditional meant the recommendations apply to most patients, but patient preference and other factors must be considered.

The recommendations for polyarthritis should be applied to children with JIA who have had more than five cumulative joints affected and not applied to children with systemic arthritis or active sacroiliitis. Several general recommendations are made for patients with polyarthritis including the use, conditionally, of methotrexate over leflunomide or sulfasalazine. Subcutaneous methotrexate is also conditionally recommended over oral methotrexate. Additionally, combination therapy with biologic plus non-biologic is conditionally recommended over biologic monotherapy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The guideline conditionally recommends that patients with polyarthritis with moderate or high disease activity should receive bridging therapy with a less than three-month course of oral glucocorticoids. The guidelines strongly recommend initial therapy with disease-modifying anti-rheumatic drugs (DMARDs), as opposed to non-steroidal anti-inflammatory drug (NSAID) monotherapy. Additionally, initial therapy with DMARDs is conditionally recommended over initial therapy with biologics. However, according to the guideline, biologics may be an appropriate initial therapy for patients with involvement of high-risk joints, high disease activity and at high risk of disabling joint damage.

The guideline also makes subsequent therapy recommendations for polyarthritis. In patients with low disease activity, escalation of therapy is conditionally recommended over no escalation. Such escalation may include intra-articular glucocorticoid injection or an increase in the dose of, or a change in, DMARD or biologic therapy. For patients with moderate or high disease activity after the first tumor necrosis factor (TNF) inhibitor, the guidelines conditionally recommend switching to a non-TNF inhibitor biologic.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Systemic Inflammatory Syndromes Tagged With: 2018 ACR/ARHP Annual Meeting, Guidelines, JIA, Juvenile idiopathic arthritisIssue: March 2019

You Might Also Like:
  • New Genetic Loci Identified, Epigenome Explored in Juvenile Idiopathic Arthritis
  • Juvenile Idiopathic Arthritis
  • Patient Fact Sheet: Juvenile Idiopathic Arthritis
  • Growing Up Confident with Juvenile Idiopathic Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)